0001193125-26-211931
SEC filingAnnexon's Q1 2026 net loss improved to $44.1M from $54.4M, driven by disciplined R&D spending as the company advances late-stage programs.
Annexon's net loss for Q1 2026 was $44.1 million, an improvement of 18.8% compared to $54.4 million in Q1 2025. The operating loss decreased 19.8% to $46.1 million from $57.4 million. The improvement was primarily attributable to a decrease in completed contract manufacturing activity for the tanruprubart European MAA filing and the vonaprument manufacturing technology transfer to a commercial-ready facility, as noted in the business context. The company remains a pre-revenue clinical-stage biopharmaceutical company with no approved products.
Net cash used in operating activities was $46.8 million in Q1 2026, compared to $50.1 million in the prior year period. Capital expenditures were negligible. Free cash flow was negative $46.8 million. The decrease in cash used was primarily due to lower average cash and investment balances. Management projects that existing cash and cash equivalents and short-term investments will enable the company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. However, the company has generated operating losses each year since inception and expects to continue incurring losses for the foreseeable future as it develops its product candidates and conducts clinical trials.
Annexon's two lead programs are tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for geographic atrophy (GA) in dry AMD. The tanruprubart MAA is under review by the EMA, and the company plans to submit a BLA to the FDA in 2026 following initial data from the ongoing FORWARD study. For vonaprument, enrollment of 659 patients in the global Phase 3 ARCHER II trial was completed in July 2025, with topline data expected in the fourth quarter of 2026. The company also continues to develop ANX1502, an oral small molecule for autoimmune conditions, with a proof-of-concept study in cold agglutinin disease ongoing.
The filing reiterates substantial doubt about the company's ability to continue as a going concern without additional financing. Key risks include the uncertainty of regulatory approval for both lead candidates, reliance on third-party manufacturers, and the need for substantial additional capital to complete development and commercialization. The company expects to continue incurring losses for the foreseeable future as it advances its pipeline through late-stage clinical trials and prepares for potential commercialization.